On September 23, 2020, Cure Pharmaceutical Holding Corp. (the “Company”) entered into an Agreement and Plan of Merger and Reorganization by and among the Company, Cure Labs Inc., a Delaware corporation and a wholly owned, subsidiary of the Company (“Merger Sub”), The Sera Labs Inc., a Delaware corporation (“Sera Labs”), and Nancy Duitch, in her capacity as the security holders representative. The Merger Agreement provides for the acquisition of Sera Labs by the Company through the merger of Merger Sub with and into Sera Labs, with Sera Labs surviving as a wholly owned, subsidiary of the Company (the “Merger”). The Merger Agreement also contemplates that at the Effective Time the Company will enter into an employment agreement with Nancy Duitch in her capacity as Chief Strategy Officer - Wellness of the Company and Chief Executive Officer of Sera Labs.